26 results on '"Fagard, R."'
Number of results to display per page
Search Results
2. Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis
- Author
-
Adler, A, Agodoa, L, Algra, A, Asselbergs, F W, Beckett, N, Berge, E, Black, H, Brouwers, F P J, Brown, M, Bulpitt, C J, Byington, B, Chalmers, J, Cushman, W C, Cutler, J, Davis, B R, Devereaux, R B, Dwyer, J, Estacio, R, Fagard, R, Fox, K, Fukui, T, Gupta, A K, Holman, R R, Imai, Y, Ishii, M, Julius, S, Kanno, Y, Kjeldsen, S E, Kostis, J, Kuramoto, K, Lanke, J, Lewis, E, Lewis, J, Lievre, M, Lindholm, L H, Lueders, S, MacMahon, S, Mancia, G, Matsuzaki, M, Mehlum, M H, Nissen, S, Ogawa, H, Ogihara, T, Ohkubo, T, Palmer, C, Patel, A, Pepine, C J, Pfeffer, M, Poulter, N R, Rakugi, H, Reboldi, G, Reid, C, Remuzzi, G, Ruggenenti, P, Saruta, T, Schrader, J, Schrier, R, Sever, P, Sleight, P, Staessen, J A, Suzuki, H, Thijs, L, Ueshima, K, Umemoto, S, van Gilst, W H, Verdecchia, P, Wachtell, K, Whelton, P, Wing, L, Woodward, M, Yui, Y, Yusuf, S, Zanchetti, A, Zhang, Z Y, Anderson, C, Baigent, C, Brenner, BM, Collins, R, de Zeeuw, D, Lubsen, J, Malacco, E, Neal, B, Perkovic, V, Pitt, B, Rodgers, A, Rothwell, P, Salimi-Khorshidi, G, Sundström, J, Turnbull, F, Viberti, G, Wang, J, Copland, Emma, Canoy, Dexter, Nazarzadeh, Milad, Bidel, Zeinab, Ramakrishnan, Rema, Woodward, Mark, Chalmers, John, Teo, Koon K, Pepine, Carl J, Davis, Barry R, Kjeldsen, Sverre, Sundström, Johan, and Rahimi, Kazem
- Published
- 2021
- Full Text
- View/download PDF
3. Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis
- Author
-
Nazarzadeh, Milad, primary, Bidel, Zeinab, additional, Canoy, Dexter, additional, Copland, Emma, additional, Bennett, Derrick A, additional, Dehghan, Abbas, additional, Davey Smith, George, additional, Holman, Rury R, additional, Woodward, Mark, additional, Gupta, Ajay, additional, Adler, Amanda I, additional, Wamil, Malgorzata, additional, Sattar, Naveed, additional, Cushman, William C, additional, McManus, Richard J, additional, Teo, Koon, additional, Davis, Barry R, additional, Chalmers, John, additional, Pepine, Carl J, additional, Rahimi, Kazem, additional, Agodoa, L, additional, Algra, A, additional, Asselbergs, F W, additional, Beckett, N, additional, Berge, E, additional, Black, H, additional, Brouwers, F P J, additional, Brown, M, additional, Bulpitt, C J, additional, Byington, B, additional, Cutler, J, additional, Devereaux, R B, additional, Dwyer, J, additional, Estacio, R, additional, Fagard, R, additional, Fox, K, additional, Fukui, T, additional, Imai, Y, additional, Ishii, M, additional, Julius, S, additional, Kanno, Y, additional, Kjeldsen, S E, additional, Kostis, J, additional, Kuramoto, K, additional, Lanke, J, additional, Lewis, E, additional, Lewis, J, additional, Lievre, M, additional, Lindholm, L H, additional, Lueders, S, additional, MacMahon, S, additional, Mancia, G, additional, Matsuzaki, M, additional, Mehlum, M H, additional, Nissen, S, additional, Ogawa, H, additional, Ogihara, T, additional, Ohkubo, T, additional, Palmer, C, additional, Patel, A, additional, Pfeffer, M, additional, Poulter, N R, additional, Rakugi, H, additional, Reboldi, G, additional, Reid, C, additional, Remuzzi, G, additional, Ruggenenti, P, additional, Saruta, T, additional, Schrader, J, additional, Schrier, R, additional, Sever, P, additional, Sleight, P, additional, Staessen, J A, additional, Suzuki, H, additional, Thijs, L, additional, Ueshima, K, additional, Umemoto, S, additional, van Gilst, W H, additional, Verdecchia, P, additional, Wachtell, K, additional, Whelton, P, additional, Wing, L, additional, Yui, Y, additional, Yusuf, S, additional, Zanchetti, A, additional, Zhang, Z Y, additional, Anderson, C, additional, Baigent, C, additional, Brenner, BM, additional, Collins, R, additional, de Zeeuw, D, additional, Lubsen, J, additional, Malacco, E, additional, Neal, B, additional, Perkovic, V, additional, Pitt, B, additional, Rodgers, A, additional, Rothwell, P, additional, Salimi-Khorshidi, G, additional, Sundström, J, additional, Turnbull, F, additional, Viberti, G, additional, and Wang, J, additional
- Published
- 2022
- Full Text
- View/download PDF
4. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis
- Author
-
Rahimi, K, Bidel, Z, Nazarzadeh, M, Copland, E, Canoy, D, Wamil, M, Majert, J, Mcmanus, R, Adler, A, Agodoa, L, Algra, A, Asselbergs, F, Beckett, N, Berge, E, Black, H, Boersma, E, Brouwers, F, Brown, M, Brugts, J, Bulpitt, C, Byington, R, Cushman, W, Cutler, J, Devereaux, R, Dwyer, J, Estacio, R, Fagard, R, Fox, K, Fukui, T, Gupta, A, Holman, R, Imai, Y, Ishii, M, Julius, S, Kanno, Y, Kjeldsen, S, Kostis, J, Kuramoto, K, Lanke, J, Lewis, E, Lewis, J, Lievre, M, Lindholm, L, Lueders, S, Macmahon, S, Mancia, G, Matsuzaki, M, Mehlum, M, Nissen, S, Ogawa, H, Ogihara, T, Ohkubo, T, Palmer, C, Patel, A, Pfeffer, M, Pitt, B, Poulter, N, Rakugi, H, Reboldi, G, Reid, C, Remuzzi, G, Ruggenenti, P, Saruta, T, Schrader, J, Schrier, R, Sever, P, Sleight, P, Staessen, J, Suzuki, H, Thijs, L, Ueshima, K, Umemoto, S, van Gilst, W, Verdecchia, P, Wachtell, K, Whelton, P, Wing, L, Woodward, M, Yui, Y, Yusuf, S, Zanchetti, A, Zhang, Z, Anderson, C, Baigent, C, Brenner, B, Collins, R, de Zeeuw, D, Lubsen, J, Malacco, E, Neal, B, Perkovic, V, Rodgers, A, Rothwell, P, Salimi-Khorshidi, G, Sundstrom, J, Turnbull, F, Viberti, G, Wang, J, Chalmers, J, Davis, B, Pepine, C, Teo, K, Rahimi K., Bidel Z., Nazarzadeh M., Copland E., Canoy D., Wamil M., Majert J., McManus R., Adler A., Agodoa L., Algra A., Asselbergs F. W., Beckett N. S., Berge E., Black H., Boersma E., Brouwers F. P. J., Brown M., Brugts J. J., Bulpitt C. J., Byington R. P., Cushman W. C., Cutler J., Devereaux R. B., Dwyer J. P., Estacio R., Fagard R., Fox K., Fukui T., Gupta A. K., Holman R. R., Imai Y., Ishii M., Julius S., Kanno Y., Kjeldsen S. E., Kostis J., Kuramoto K., Lanke J., Lewis E., Lewis J. B., Lievre M., Lindholm L. H., Lueders S., MacMahon S., Mancia G., Matsuzaki M., Mehlum M. H., Nissen S., Ogawa H., Ogihara T., Ohkubo T., Palmer C. R., Patel A., Pfeffer M. A., Pitt B., Poulter N. R., Rakugi H., Reboldi G., Reid C., Remuzzi G., Ruggenenti P., Saruta T., Schrader J., Schrier R., Sever P., Sleight P., Staessen J. A., Suzuki H., Thijs L., Ueshima K., Umemoto S., van Gilst W. H., Verdecchia P., Wachtell K., Whelton P., Wing L., Woodward M., Yui Y., Yusuf S., Zanchetti A., Zhang Z. -Y., Anderson C., Baigent C., Brenner B. M., Collins R., de Zeeuw D., Lubsen J., Malacco E., Neal B., Perkovic V., Rodgers A., Rothwell P., Salimi-Khorshidi G., Sundstrom J., Turnbull F., Viberti G., Wang J., Chalmers J., Davis B. R., Pepine C. J., Teo K. K., Rahimi, K, Bidel, Z, Nazarzadeh, M, Copland, E, Canoy, D, Wamil, M, Majert, J, Mcmanus, R, Adler, A, Agodoa, L, Algra, A, Asselbergs, F, Beckett, N, Berge, E, Black, H, Boersma, E, Brouwers, F, Brown, M, Brugts, J, Bulpitt, C, Byington, R, Cushman, W, Cutler, J, Devereaux, R, Dwyer, J, Estacio, R, Fagard, R, Fox, K, Fukui, T, Gupta, A, Holman, R, Imai, Y, Ishii, M, Julius, S, Kanno, Y, Kjeldsen, S, Kostis, J, Kuramoto, K, Lanke, J, Lewis, E, Lewis, J, Lievre, M, Lindholm, L, Lueders, S, Macmahon, S, Mancia, G, Matsuzaki, M, Mehlum, M, Nissen, S, Ogawa, H, Ogihara, T, Ohkubo, T, Palmer, C, Patel, A, Pfeffer, M, Pitt, B, Poulter, N, Rakugi, H, Reboldi, G, Reid, C, Remuzzi, G, Ruggenenti, P, Saruta, T, Schrader, J, Schrier, R, Sever, P, Sleight, P, Staessen, J, Suzuki, H, Thijs, L, Ueshima, K, Umemoto, S, van Gilst, W, Verdecchia, P, Wachtell, K, Whelton, P, Wing, L, Woodward, M, Yui, Y, Yusuf, S, Zanchetti, A, Zhang, Z, Anderson, C, Baigent, C, Brenner, B, Collins, R, de Zeeuw, D, Lubsen, J, Malacco, E, Neal, B, Perkovic, V, Rodgers, A, Rothwell, P, Salimi-Khorshidi, G, Sundstrom, J, Turnbull, F, Viberti, G, Wang, J, Chalmers, J, Davis, B, Pepine, C, Teo, K, Rahimi K., Bidel Z., Nazarzadeh M., Copland E., Canoy D., Wamil M., Majert J., McManus R., Adler A., Agodoa L., Algra A., Asselbergs F. W., Beckett N. S., Berge E., Black H., Boersma E., Brouwers F. P. J., Brown M., Brugts J. J., Bulpitt C. J., Byington R. P., Cushman W. C., Cutler J., Devereaux R. B., Dwyer J. P., Estacio R., Fagard R., Fox K., Fukui T., Gupta A. K., Holman R. R., Imai Y., Ishii M., Julius S., Kanno Y., Kjeldsen S. E., Kostis J., Kuramoto K., Lanke J., Lewis E., Lewis J. B., Lievre M., Lindholm L. H., Lueders S., MacMahon S., Mancia G., Matsuzaki M., Mehlum M. H., Nissen S., Ogawa H., Ogihara T., Ohkubo T., Palmer C. R., Patel A., Pfeffer M. A., Pitt B., Poulter N. R., Rakugi H., Reboldi G., Reid C., Remuzzi G., Ruggenenti P., Saruta T., Schrader J., Schrier R., Sever P., Sleight P., Staessen J. A., Suzuki H., Thijs L., Ueshima K., Umemoto S., van Gilst W. H., Verdecchia P., Wachtell K., Whelton P., Wing L., Woodward M., Yui Y., Yusuf S., Zanchetti A., Zhang Z. -Y., Anderson C., Baigent C., Brenner B. M., Collins R., de Zeeuw D., Lubsen J., Malacco E., Neal B., Perkovic V., Rodgers A., Rothwell P., Salimi-Khorshidi G., Sundstrom J., Turnbull F., Viberti G., Wang J., Chalmers J., Davis B. R., Pepine C. J., and Teo K. K.
- Abstract
Background: The effects of pharmacological blood-pressure-lowering on cardiovascular outcomes in individuals aged 70 years and older, particularly when blood pressure is not substantially increased, is uncertain. We compared the effects of blood-pressure-lowering treatment on the risk of major cardiovascular events in groups of patients stratified by age and blood pressure at baseline. Methods: We did a meta-analysis using individual participant-level data from randomised controlled trials of pharmacological blood-pressure-lowering versus placebo or other classes of blood-pressure-lowering medications, or between more versus less intensive treatment strategies, which had at least 1000 persons-years of follow-up in each treatment group. Participants with previous history of heart failure were excluded. Data were obtained from the Blood Pressure Lowering Treatment Triallists' Collaboration. We pooled the data and categorised participants into baseline age groups (<55 years, 55–64 years, 65–74 years, 75–84 years, and ≥85 years) and blood pressure categories (in 10 mm Hg increments from <120 mm Hg to ≥170 mm Hg systolic blood pressure and from <70 mm Hg to ≥110 mm Hg diastolic). We used a fixed effects one-stage approach and applied Cox proportional hazard models, stratified by trial, to analyse the data. The primary outcome was defined as either a composite of fatal or non-fatal stroke, fatal or non-fatal myocardial infarction or ischaemic heart disease, or heart failure causing death or requiring hospital admission. Findings: We included data from 358 707 participants from 51 randomised clinical trials. The age of participants at randomisation ranged from 21 years to 105 years (median 65 years [IQR 59–75]), with 42 960 (12·0%) participants younger than 55 years, 128 437 (35·8%) aged 55–64 years, 128 506 (35·8%) 65–74 years, 54 016 (15·1%) 75–84 years, and 4788 (1·3%) 85 years and older. The hazard ratios for the risk of major cardiovascular events per 5 mm Hg
- Published
- 2021
5. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis
- Author
-
Adler, A, Agodoa, L, Algra, A, Asselbergs, F, Beckett, N, Berge, E, Black, H, Brouwers, F, Brown, M, Bulpitt, C, Byington, R, Chalmers, J, Cushman, W, Cutler, J, Davis, B, Devereaux, R, Dwyer, J, Estacio, R, Fagard, R, Fox, K, Fukui, T, Gupta, A, Holman, R, Imai, Y, Ishii, M, Julius, S, Kanno, Y, Kjeldsen, S, Kostis, J, Kuramoto, K, Lanke, J, Lewis, E, Lewis, J, Lievre, M, Lindholm, L, Lueders, S, Macmahon, S, Mancia, G, Matsuzaki, M, Mehlum, M, Nissen, S, Ogawa, H, Ogihara, T, Ohkubo, T, Palmer, C, Patel, A, Pepine, C, Pfeffer, M, Pitt, B, Poulter, N, Rakugi, H, Reboldi, G, Reid, C, Remuzzi, G, Ruggenenti, P, Saruta, T, Schrader, J, Schrier, R, Sever, P, Sleight, P, Staessen, J, Suzuki, H, Thijs, L, Ueshima, K, Umemoto, S, van Gilst, W, Verdecchia, P, Wachtell, K, Whelton, P, Wing, L, Woodward, M, Yui, Y, Yusuf, S, Zanchetti, A, Zhang, Z, Anderson, C, Baigent, C, Brenner, B, Collins, R, de Zeeuw, D, Lubsen, J, Malacco, E, Neal, B, Perkovic, V, Rodgers, A, Rothwell, P, Salimi-Khorshidi, G, Sundstrom, J, Turnbull, F, Viberti, G, Wang, J, Adler A., Agodoa L., Algra A., Asselbergs F. W., Beckett N. S., Berge E., Black H., Brouwers F. P. J., Brown M., Bulpitt C. J., Byington R. P., Chalmers J., Cushman W. C., Cutler J., Davis B. R., Devereaux R. B., Dwyer J., Estacio R., Fagard R., Fox K., Fukui T., Gupta A. K., Holman R. R., Imai Y., Ishii M., Julius S., Kanno Y., Kjeldsen S. E., Kostis J., Kuramoto K., Lanke J., Lewis E., Lewis J. B., Lievre M., Lindholm L. H., Lueders S., MacMahon S., Mancia G., Matsuzaki M., Mehlum M. H., Nissen S., Ogawa H., Ogihara T., Ohkubo T., Palmer C. R., Patel A., Pepine C. J., Pfeffer M. A., Pitt B., Poulter N. R., Rakugi H., Reboldi G., Reid C., Remuzzi G., Ruggenenti P., Saruta T., Schrader J., Schrier R., Sever P., Sleight P., Staessen J. A., Suzuki H., Thijs L., Ueshima K., Umemoto S., van Gilst W. H., Verdecchia P., Wachtell K., Whelton P., Wing L., Woodward M., Yui Y., Yusuf S., Zanchetti A., Zhang Z. -Y., Anderson C., Baigent C., Brenner B. M., Collins R., de Zeeuw D., Lubsen J., Malacco E., Neal B., Perkovic V., Rodgers A., Rothwell P., Salimi-Khorshidi G., Sundstrom J., Turnbull F., Viberti G., Wang J., Adler, A, Agodoa, L, Algra, A, Asselbergs, F, Beckett, N, Berge, E, Black, H, Brouwers, F, Brown, M, Bulpitt, C, Byington, R, Chalmers, J, Cushman, W, Cutler, J, Davis, B, Devereaux, R, Dwyer, J, Estacio, R, Fagard, R, Fox, K, Fukui, T, Gupta, A, Holman, R, Imai, Y, Ishii, M, Julius, S, Kanno, Y, Kjeldsen, S, Kostis, J, Kuramoto, K, Lanke, J, Lewis, E, Lewis, J, Lievre, M, Lindholm, L, Lueders, S, Macmahon, S, Mancia, G, Matsuzaki, M, Mehlum, M, Nissen, S, Ogawa, H, Ogihara, T, Ohkubo, T, Palmer, C, Patel, A, Pepine, C, Pfeffer, M, Pitt, B, Poulter, N, Rakugi, H, Reboldi, G, Reid, C, Remuzzi, G, Ruggenenti, P, Saruta, T, Schrader, J, Schrier, R, Sever, P, Sleight, P, Staessen, J, Suzuki, H, Thijs, L, Ueshima, K, Umemoto, S, van Gilst, W, Verdecchia, P, Wachtell, K, Whelton, P, Wing, L, Woodward, M, Yui, Y, Yusuf, S, Zanchetti, A, Zhang, Z, Anderson, C, Baigent, C, Brenner, B, Collins, R, de Zeeuw, D, Lubsen, J, Malacco, E, Neal, B, Perkovic, V, Rodgers, A, Rothwell, P, Salimi-Khorshidi, G, Sundstrom, J, Turnbull, F, Viberti, G, Wang, J, Adler A., Agodoa L., Algra A., Asselbergs F. W., Beckett N. S., Berge E., Black H., Brouwers F. P. J., Brown M., Bulpitt C. J., Byington R. P., Chalmers J., Cushman W. C., Cutler J., Davis B. R., Devereaux R. B., Dwyer J., Estacio R., Fagard R., Fox K., Fukui T., Gupta A. K., Holman R. R., Imai Y., Ishii M., Julius S., Kanno Y., Kjeldsen S. E., Kostis J., Kuramoto K., Lanke J., Lewis E., Lewis J. B., Lievre M., Lindholm L. H., Lueders S., MacMahon S., Mancia G., Matsuzaki M., Mehlum M. H., Nissen S., Ogawa H., Ogihara T., Ohkubo T., Palmer C. R., Patel A., Pepine C. J., Pfeffer M. A., Pitt B., Poulter N. R., Rakugi H., Reboldi G., Reid C., Remuzzi G., Ruggenenti P., Saruta T., Schrader J., Schrier R., Sever P., Sleight P., Staessen J. A., Suzuki H., Thijs L., Ueshima K., Umemoto S., van Gilst W. H., Verdecchia P., Wachtell K., Whelton P., Wing L., Woodward M., Yui Y., Yusuf S., Zanchetti A., Zhang Z. -Y., Anderson C., Baigent C., Brenner B. M., Collins R., de Zeeuw D., Lubsen J., Malacco E., Neal B., Perkovic V., Rodgers A., Rothwell P., Salimi-Khorshidi G., Sundstrom J., Turnbull F., Viberti G., and Wang J.
- Abstract
Background: The effects of pharmacological blood pressure lowering at normal or high-normal blood pressure ranges in people with or without pre-existing cardiovascular disease remains uncertain. We analysed individual participant data from randomised trials to investigate the effects of blood pressure lowering treatment on the risk of major cardiovascular events by baseline levels of systolic blood pressure. Methods: We did a meta-analysis of individual participant-level data from 48 randomised trials of pharmacological blood pressure lowering medications versus placebo or other classes of blood pressure-lowering medications, or between more versus less intensive treatment regimens, which had at least 1000 persons-years of follow-up in each group. Trials exclusively done with participants with heart failure or short-term interventions in participants with acute myocardial infarction or other acute settings were excluded. Data from 51 studies published between 1972 and 2013 were obtained by the Blood Pressure Lowering Treatment Trialists' Collaboration (Oxford University, Oxford, UK). We pooled the data to investigate the stratified effects of blood pressure-lowering treatment in participants with and without prevalent cardiovascular disease (ie, any reports of stroke, myocardial infarction, or ischaemic heart disease before randomisation), overall and across seven systolic blood pressure categories (ranging from <120 to ≥170 mm Hg). The primary outcome was a major cardiovascular event (defined as a composite of fatal and non-fatal stroke, fatal or non-fatal myocardial infarction or ischaemic heart disease, or heart failure causing death or requiring admission to hospital), analysed as per intention to treat. Findings: Data for 344 716 participants from 48 randomised clinical trials were available for this analysis. Pre-randomisation mean systolic/diastolic blood pressures were 146/84 mm Hg in participants with previous cardiovascular disease (n=157 728) and 157/8
- Published
- 2021
6. Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis
- Author
-
Copland, Emma, primary, Canoy, Dexter, additional, Nazarzadeh, Milad, additional, Bidel, Zeinab, additional, Ramakrishnan, Rema, additional, Woodward, Mark, additional, Chalmers, John, additional, Teo, Koon K, additional, Pepine, Carl J, additional, Davis, Barry R, additional, Kjeldsen, Sverre, additional, Sundström, Johan, additional, Rahimi, Kazem, additional, Adler, A, additional, Agodoa, L, additional, Algra, A, additional, Asselbergs, F W, additional, Beckett, N, additional, Berge, E, additional, Black, H, additional, Brouwers, F P J, additional, Brown, M, additional, Bulpitt, C J, additional, Byington, B, additional, Chalmers, J, additional, Cushman, W C, additional, Cutler, J, additional, Davis, B R, additional, Devereaux, R B, additional, Dwyer, J, additional, Estacio, R, additional, Fagard, R, additional, Fox, K, additional, Fukui, T, additional, Gupta, A K, additional, Holman, R R, additional, Imai, Y, additional, Ishii, M, additional, Julius, S, additional, Kanno, Y, additional, Kjeldsen, S E, additional, Kostis, J, additional, Kuramoto, K, additional, Lanke, J, additional, Lewis, E, additional, Lewis, J, additional, Lievre, M, additional, Lindholm, L H, additional, Lueders, S, additional, MacMahon, S, additional, Mancia, G, additional, Matsuzaki, M, additional, Mehlum, M H, additional, Nissen, S, additional, Ogawa, H, additional, Ogihara, T, additional, Ohkubo, T, additional, Palmer, C, additional, Patel, A, additional, Pepine, C J, additional, Pfeffer, M, additional, Poulter, N R, additional, Rakugi, H, additional, Reboldi, G, additional, Reid, C, additional, Remuzzi, G, additional, Ruggenenti, P, additional, Saruta, T, additional, Schrader, J, additional, Schrier, R, additional, Sever, P, additional, Sleight, P, additional, Staessen, J A, additional, Suzuki, H, additional, Thijs, L, additional, Ueshima, K, additional, Umemoto, S, additional, van Gilst, W H, additional, Verdecchia, P, additional, Wachtell, K, additional, Whelton, P, additional, Wing, L, additional, Woodward, M, additional, Yui, Y, additional, Yusuf, S, additional, Zanchetti, A, additional, Zhang, Z Y, additional, Anderson, C, additional, Baigent, C, additional, Brenner, BM, additional, Collins, R, additional, de Zeeuw, D, additional, Lubsen, J, additional, Malacco, E, additional, Neal, B, additional, Perkovic, V, additional, Pitt, B, additional, Rodgers, A, additional, Rothwell, P, additional, Salimi-Khorshidi, G, additional, Sundström, J, additional, Turnbull, F, additional, Viberti, G, additional, and Wang, J, additional
- Published
- 2021
- Full Text
- View/download PDF
7. 2018 ESC/ESH guidelines for the diagnosis and treatment of arterial hypertension: The Task Force for the Diagnosis and Treatment of Arterial Hypertension of the European Society of Cardiology (ESC) and of the European Society of Hypertension (ESH)
- Author
-
Williams, B, Mancia, G, Spiering, W, Rosei, E, Azizi, M, Burnier, M, Clement, D, Coca, A, De Simone, G, Dominiczak, A, Kahan, T, Mahfoud, F, Redon, J, Ruilope, L, Zanchetti, A, Kerins, M, Kjeldsen, S, Kreutz, R, Laurent, S, Lip, G, Mcmanus, R, Narkiewicz, K, Ruschitzka, F, Schmieder, R, Shlyakhto, E, Tsioufis, C, Aboyans, V, Desormais, I, De Backer, G, Heagerty, A, Agewall, S, Bochud, M, Borghi, C, Boutouyrie, P, Brguljan, J, Bueno, H, Caiani, E, Carlberg, B, Chapman, N, Cifkova, R, Cleland, J, Collet, J, Coman, I, De Leeuw, P, Delgado, V, Dendale, P, Diener, H, Dorobantu, M, Fagard, R, Farsang, C, Ferrini, M, Graham, I, Grassi, G, Haller, H, Richard Hobbs, F, Jelakovic, B, Jennings, C, Katus, H, Kroon, A, Leclercq, C, Lovic, D, Lurbe, E, Manolis, A, Mcdonagh, T, Messerli, F, Muiesan, M, Nixdorff, U, Olsen, M, Parati, G, Perk, J, Piepoli, M, Polonia, J, Ponikowski, P, Richter, D, Rimoldi, S, Roffi, M, Sattar, N, Seferovic, P, Simpson, I, Sousa-Uva, M, Stanton, A, Van De Borne, P, Vardas, P, Volpe, M, Wassmann, S, Windecker, S, Zamorano, J, Williams B., Mancia G., Spiering W., Rosei E. A., Azizi M., Burnier M., Clement D. L., Coca A., De Simone G., Dominiczak A., Kahan T., Mahfoud F., Redon J., Ruilope L., Zanchetti A., Kerins M., Kjeldsen S. E., Kreutz R., Laurent S., Lip G. Y. H., McManus R., Narkiewicz K., Ruschitzka F., Schmieder R. E., Shlyakhto E., Tsioufis C., Aboyans V., Desormais I., De Backer G., Heagerty A. M., Agewall S., Bochud M., Borghi C., Boutouyrie P., Brguljan J., Bueno H., Caiani E. G., Carlberg B., Chapman N., Cifkova R., Cleland J. G. F., Collet J. -P., Coman I. M., De Leeuw P. W., Delgado V., Dendale P., Diener H. -C., Dorobantu M., Fagard R., Farsang C., Ferrini M., Graham I. M., Grassi G., Haller H., Richard Hobbs F. D., Jelakovic B., Jennings C., Katus H. A., Kroon A. A., Leclercq C., Lovic D., Lurbe E., Manolis A. J., McDonagh T. A., Messerli F., Muiesan M. L., Nixdorff U., Olsen M. H., Parati G., Perk J., Piepoli M. F., Polonia J., Ponikowski P., Richter D. J., Rimoldi S. F., Roffi M., Sattar N., Seferovic P. M., Simpson I. A., Sousa-Uva M., Stanton A. V., Van De Borne P., Vardas P., Volpe M., Wassmann S., Windecker S., Zamorano J. L., Williams, B, Mancia, G, Spiering, W, Rosei, E, Azizi, M, Burnier, M, Clement, D, Coca, A, De Simone, G, Dominiczak, A, Kahan, T, Mahfoud, F, Redon, J, Ruilope, L, Zanchetti, A, Kerins, M, Kjeldsen, S, Kreutz, R, Laurent, S, Lip, G, Mcmanus, R, Narkiewicz, K, Ruschitzka, F, Schmieder, R, Shlyakhto, E, Tsioufis, C, Aboyans, V, Desormais, I, De Backer, G, Heagerty, A, Agewall, S, Bochud, M, Borghi, C, Boutouyrie, P, Brguljan, J, Bueno, H, Caiani, E, Carlberg, B, Chapman, N, Cifkova, R, Cleland, J, Collet, J, Coman, I, De Leeuw, P, Delgado, V, Dendale, P, Diener, H, Dorobantu, M, Fagard, R, Farsang, C, Ferrini, M, Graham, I, Grassi, G, Haller, H, Richard Hobbs, F, Jelakovic, B, Jennings, C, Katus, H, Kroon, A, Leclercq, C, Lovic, D, Lurbe, E, Manolis, A, Mcdonagh, T, Messerli, F, Muiesan, M, Nixdorff, U, Olsen, M, Parati, G, Perk, J, Piepoli, M, Polonia, J, Ponikowski, P, Richter, D, Rimoldi, S, Roffi, M, Sattar, N, Seferovic, P, Simpson, I, Sousa-Uva, M, Stanton, A, Van De Borne, P, Vardas, P, Volpe, M, Wassmann, S, Windecker, S, Zamorano, J, Williams B., Mancia G., Spiering W., Rosei E. A., Azizi M., Burnier M., Clement D. L., Coca A., De Simone G., Dominiczak A., Kahan T., Mahfoud F., Redon J., Ruilope L., Zanchetti A., Kerins M., Kjeldsen S. E., Kreutz R., Laurent S., Lip G. Y. H., McManus R., Narkiewicz K., Ruschitzka F., Schmieder R. E., Shlyakhto E., Tsioufis C., Aboyans V., Desormais I., De Backer G., Heagerty A. M., Agewall S., Bochud M., Borghi C., Boutouyrie P., Brguljan J., Bueno H., Caiani E. G., Carlberg B., Chapman N., Cifkova R., Cleland J. G. F., Collet J. -P., Coman I. M., De Leeuw P. W., Delgado V., Dendale P., Diener H. -C., Dorobantu M., Fagard R., Farsang C., Ferrini M., Graham I. M., Grassi G., Haller H., Richard Hobbs F. D., Jelakovic B., Jennings C., Katus H. A., Kroon A. A., Leclercq C., Lovic D., Lurbe E., Manolis A. J., McDonagh T. A., Messerli F., Muiesan M. L., Nixdorff U., Olsen M. H., Parati G., Perk J., Piepoli M. F., Polonia J., Ponikowski P., Richter D. J., Rimoldi S. F., Roffi M., Sattar N., Seferovic P. M., Simpson I. A., Sousa-Uva M., Stanton A. V., Van De Borne P., Vardas P., Volpe M., Wassmann S., Windecker S., and Zamorano J. L.
- Published
- 2018
8. 2018 ESC/ESH guidelines for the diagnosis and treatment of arterial hypertension: The Task Force for the Diagnosis and Treatment of Arterial Hypertension of the European Society of Cardiology (ESC) and of the European Society of Hypertension (ESH)
- Author
-
Williams B., Mancia G., Spiering W., Rosei E. A., Azizi M., Burnier M., Clement D. L., Coca A., De Simone G., Dominiczak A., Kahan T., Mahfoud F., Redon J., Ruilope L., Zanchetti A., Kerins M., Kjeldsen S. E., Kreutz R., Laurent S., Lip G. Y. H., McManus R., Narkiewicz K., Ruschitzka F., Schmieder R. E., Shlyakhto E., Tsioufis C., Aboyans V., Desormais I., De Backer G., Heagerty A. M., Agewall S., Bochud M., Borghi C., Boutouyrie P., Brguljan J., Bueno H., Caiani E. G., Carlberg B., Chapman N., Cifkova R., Cleland J. G. F., Collet J. -P., Coman I. M., De Leeuw P. W., Delgado V., Dendale P., Diener H. -C., Dorobantu M., Fagard R., Farsang C., Ferrini M., Graham I. M., Grassi G., Haller H., Richard Hobbs F. D., Jelakovic B., Jennings C., Katus H. A., Kroon A. A., Leclercq C., Lovic D., Lurbe E., Manolis A. J., McDonagh T. A., Messerli F., Muiesan M. L., Nixdorff U., Olsen M. H., Parati G., Perk J., Piepoli M. F., Polonia J., Ponikowski P., Richter D. J., Rimoldi S. F., Roffi M., Sattar N., Seferovic P. M., Simpson I. A., Sousa-Uva M., Stanton A. V., Van De Borne P., Vardas P., Volpe M., Wassmann S., Windecker S., Zamorano J. L., Williams, B, Mancia, G, Spiering, W, Rosei, E, Azizi, M, Burnier, M, Clement, D, Coca, A, De Simone, G, Dominiczak, A, Kahan, T, Mahfoud, F, Redon, J, Ruilope, L, Zanchetti, A, Kerins, M, Kjeldsen, S, Kreutz, R, Laurent, S, Lip, G, Mcmanus, R, Narkiewicz, K, Ruschitzka, F, Schmieder, R, Shlyakhto, E, Tsioufis, C, Aboyans, V, Desormais, I, De Backer, G, Heagerty, A, Agewall, S, Bochud, M, Borghi, C, Boutouyrie, P, Brguljan, J, Bueno, H, Caiani, E, Carlberg, B, Chapman, N, Cifkova, R, Cleland, J, Collet, J, Coman, I, De Leeuw, P, Delgado, V, Dendale, P, Diener, H, Dorobantu, M, Fagard, R, Farsang, C, Ferrini, M, Graham, I, Grassi, G, Haller, H, Richard Hobbs, F, Jelakovic, B, Jennings, C, Katus, H, Kroon, A, Leclercq, C, Lovic, D, Lurbe, E, Manolis, A, Mcdonagh, T, Messerli, F, Muiesan, M, Nixdorff, U, Olsen, M, Parati, G, Perk, J, Piepoli, M, Polonia, J, Ponikowski, P, Richter, D, Rimoldi, S, Roffi, M, Sattar, N, Seferovic, P, Simpson, I, Sousa-Uva, M, Stanton, A, Van De Borne, P, Vardas, P, Volpe, M, Wassmann, S, Windecker, S, and Zamorano, J
- Subjects
diagnosis and treatment of arterial hypertension - Published
- 2018
9. Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: A meta-analysis of randomised trials
- Author
-
Agodoa, L, Estacio, R, Schrier, R, Lubsen, J, Chalmers, J, Cutler, J, Davis, B, Wing, L, Poulter, N, Sever, P, Remuzzi, G, Ruggenenti, P, Nissen, S, Lindholm, L, Fukui, T, Ogihara, T, Saruta, T, Black, H, Sleight, P, Lievre, M, Suzuki, H, Fox, K, Lisheng, L, Ohkubo, T, Imai, Y, Yusuf, S, Bulpitt, C, Lewis, E, Brown, M, Palmer, C, Wang, J, Pepine, C, Ishii, M, Yui, Y, Kuramoto, K, Pfeff Er, M, Asselbergs, F, Van Gilst, W, Byington, B, Pitt, B, Brenner, B, Remme, W, De Zeeuw, D, Rahman, M, Viberti, G, Teo, K, Zanchetti, A, Malacco, E, Mancia, G, Staessen, J, Fagard, R, Holman, R, Hansson, L, Kostis, J, Kanno, Y, Lueders, S, Matsuzaki, M, Poole-Wilson, P, Schrader, J, Rahimi, K, Anderson, C, Chapman, N, Collins, R, Macmahon, S, Neal, B, Rodgers, A, Whelton, P, Woodward, M, Agodoa L., Estacio R., Schrier R., Lubsen J., Chalmers J., Cutler J., Davis B., Wing L., Poulter N. R., Sever P., Remuzzi G., Ruggenenti P., Nissen S., Lindholm L. H., Fukui T., Ogihara T., Saruta T., Black H., Sleight P., Lievre M., Suzuki H., Fox K., Lisheng L., Ohkubo T., Imai Y., Yusuf S., Bulpitt C. J., Lewis E., Brown M., Palmer C., Wang J., Pepine C., Ishii M., Yui Y., Kuramoto K., Pfeff Er M., Asselbergs F. W., Van Gilst W. H., Byington B., Pitt B., Brenner B., Remme W. J., De Zeeuw D., Rahman M., Viberti G., Teo K., Zanchetti A., Malacco E., Mancia G., Staessen J., Fagard R., Holman R., Hansson L., Kostis J., Kanno Y., Lueders S., Matsuzaki M., Poole-Wilson P., Schrader J., Rahimi K., Anderson C., Chapman N., Collins R., MacMahon S., Neal B., Rodgers A., Whelton P., Woodward M., Agodoa, L, Estacio, R, Schrier, R, Lubsen, J, Chalmers, J, Cutler, J, Davis, B, Wing, L, Poulter, N, Sever, P, Remuzzi, G, Ruggenenti, P, Nissen, S, Lindholm, L, Fukui, T, Ogihara, T, Saruta, T, Black, H, Sleight, P, Lievre, M, Suzuki, H, Fox, K, Lisheng, L, Ohkubo, T, Imai, Y, Yusuf, S, Bulpitt, C, Lewis, E, Brown, M, Palmer, C, Wang, J, Pepine, C, Ishii, M, Yui, Y, Kuramoto, K, Pfeff Er, M, Asselbergs, F, Van Gilst, W, Byington, B, Pitt, B, Brenner, B, Remme, W, De Zeeuw, D, Rahman, M, Viberti, G, Teo, K, Zanchetti, A, Malacco, E, Mancia, G, Staessen, J, Fagard, R, Holman, R, Hansson, L, Kostis, J, Kanno, Y, Lueders, S, Matsuzaki, M, Poole-Wilson, P, Schrader, J, Rahimi, K, Anderson, C, Chapman, N, Collins, R, Macmahon, S, Neal, B, Rodgers, A, Whelton, P, Woodward, M, Agodoa L., Estacio R., Schrier R., Lubsen J., Chalmers J., Cutler J., Davis B., Wing L., Poulter N. R., Sever P., Remuzzi G., Ruggenenti P., Nissen S., Lindholm L. H., Fukui T., Ogihara T., Saruta T., Black H., Sleight P., Lievre M., Suzuki H., Fox K., Lisheng L., Ohkubo T., Imai Y., Yusuf S., Bulpitt C. J., Lewis E., Brown M., Palmer C., Wang J., Pepine C., Ishii M., Yui Y., Kuramoto K., Pfeff Er M., Asselbergs F. W., Van Gilst W. H., Byington B., Pitt B., Brenner B., Remme W. J., De Zeeuw D., Rahman M., Viberti G., Teo K., Zanchetti A., Malacco E., Mancia G., Staessen J., Fagard R., Holman R., Hansson L., Kostis J., Kanno Y., Lueders S., Matsuzaki M., Poole-Wilson P., Schrader J., Rahimi K., Anderson C., Chapman N., Collins R., MacMahon S., Neal B., Rodgers A., Whelton P., and Woodward M.
- Abstract
Summary Background The cardiovascular benefits of blood pressure lowering in obese people compared with people of normal weight might depend on choice of drug. We compared the effects of blood pressure-lowering regimens on cardiovascular risk in groups of patients categorised by baseline body-mass index (BMI). Methods We used individual patient data from trials included in the Blood Pressure Lowering Treatment Trialists' Collaboration to compare the effects of different classes of blood pressure-lowering regimens for the primary outcome of total major cardiovascular events (stroke, coronary heart disease, heart failure, and cardiovascular death). We used meta-analyses and meta-regressions to assess interactions between treatment and BMI when fitted as either a categorical variable (<25 kg/m2, 25 to <30 kg/m2, and ≥30 kg/m2) or a continuous variable. Findings Analyses were based on 135 715 individuals from 22 trials who had 14 353 major cardiovascular events. None of the six primary comparisons showed evidence that protection varied by drug class across the three BMI groups (all p for trend >0·20). When analysed as a continuous variable, angiotensin-converting-enzyme inhibitors gave slightly greater protection for each 5 kg/m2 higher BMI than did calcium antagonists (hazard ratio 0·93, 95% CI 0·89-0·98; p=0·004) or diuretics (0·93, 0·89-0·98; p=0·002). The meta-regressions showed no relation between BMI category and the risk reduction for a given fall in systolic blood pressure. By contrast with a previous report, we noted no relation between BMI and the efficacy of calcium antagonists compared with diuretics. Interpretation We found little evidence that selection of a particular class of blood pressure-lowering drug will lead to substantially different outcomes for individuals who are obese compared with those who are lean. Funding None.
- Published
- 2015
10. Investigating the stratified efficacy and safety of pharmacological blood pressure-lowering: an overall protocol for individual patient-level data meta-analyses of over 300 000 randomised participants in the new phase of the Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC)
- Author
-
Rahimi, K, Canoy, D, Nazarzadeh, M, Salimi-Khorshidi, G, Woodward, M, Teo, K, Davis, BR, Chalmers, J, Pepine, CJ, Agodoa, L, Algra, A, Asselbergs, FW, Beckett, N, Berge, E, Black, H, Brouwers, FPJ, Brown, M, Bulpitt, CJ, Byington, B, Cutler, J, Devereaux, RB, Dwyer, D, Fagard, R, Fox, K, Fukui, T, Gupta, AJ, Holman, RR, Imai, Y, Ishii, M, Julius, S, Kanno, Y, Kjeldsen, SE, Kostis, J, Kuramoto, K, Lanke, J, Lewis, E, Lievre, M, Lindholm, LH, Lueders, S, MacMahon, S, Matsuzaki, M, Mehlum, MH, Nissen, S, Ogawa, H, Othisgihara, T, Ohkubo, T, Palmer, C, Patel, A, Pepine, C, Pfeffer, M, Poulter, NR, Rakugi, H, Remuzzi, G, Ruggenenti, P, Saruta, T, Schrader, J, Schrier, R, Sever, P, Sleight, P, Staessen, JA, Suzuki, H, Thijs, L, Ueshima, K, Umemoto, S, Van Gilst, WH, Verdecchia, P, Wachtell, K, Yui, Y, Yusuf, S, Baigent, C, Collins, R, De Zeeuw, D, Neal, B, Perkovic, V, Rahman, M, Remme, WJ, Rodgers, A, Sundstrom, J, Turnbull, F, Foundation for Circulatory Health, Cardiovascular Centre (CVC), Groningen Kidney Center (GKC), and Staessen, Jan
- Subjects
medicine.medical_specialty ,Epidemiology ,Disease ,REGIMENS ,030204 cardiovascular system & hematology ,Research Support ,Phase (combat) ,03 medical and health sciences ,Medicine, General & Internal ,0302 clinical medicine ,General & Internal Medicine ,Diabetes mellitus ,Protocol ,medicine ,Journal Article ,Humans ,030212 general & internal medicine ,Intensive care medicine ,Non-U.S. Gov't ,Stroke ,Antihypertensive Agents ,Randomized Controlled Trials as Topic ,RISK ,Protocol (science) ,Medicine(all) ,Science & Technology ,efficacy and safety of bp lowering treatment ,HYPERTENSION ,business.industry ,Research Support, Non-U.S. Gov't ,blood pressure ,General Medicine ,medicine.disease ,PROSPECTIVELY-DESIGNED OVERVIEWS ,MODEL ,Treatment Outcome ,MAJOR CARDIOVASCULAR EVENTS ,Blood pressure ,Patient level data ,meta-analyses ,Blood pressure lowering ,business ,Life Sciences & Biomedicine ,Blood Pressure Lowering Treatment Trialists’ Collaboration - Abstract
IntroductionPrevious research from the Blood Pressure Lowering Treatment Trialists’ Collaboration (BPLTTC) and others has shown that pharmacological blood pressure (BP)- lowering substantially reduces the risk of major cardiovascular events, including ischaemic heart disease, heart failure and stroke. In this new phase, the aim is to conduct individual patient-level data (IPD) meta-analyses involving eligible BP-lowering randomised controlled trials (RCTs) to address uncertainties relating to efficacy and safety of BP-lowering treatment.Methods and analysisRCTs investigating the effect of pharmacological BP-lowering, with a minimum of 1000 patient-years of follow-up in each trial arm, are eligible. Our systematic review identified 100 potentially eligible trials. We requested their investigators/sponsors to contribute baseline, follow-up and outcomes data. As of June 2018, the collaboration has obtained data from 49 trials (n=315 046 participants), with additional data currently in the process of being transferred from four RCTs (n=34 642 participants). In addition, data harmonisation has commenced. Scientific activities of the collaboration are overseen by the Steering Committee with input from all collaborators. Detailed protocols for individual meta-analyses will be developed and registered on public platforms.Ethics and disseminationEthics approval has been obtained for this new and extended phase of the BPLTTC, the largest collaboration of de-identified IPD from RCTs. It offers an efficient and ethical manner of re-purposing existing data to answer clinically important questions relating to BP treatment as well as methodological questions relating to IPD meta-analyses. Among the immediate impacts will include reliable quantification of effects of treatment modifiers, such as baseline BP, age and prior disease, on both vascular and non-vascular outcomes. Analyses will further assess the impact of BP-lowering on important, but less well understood, outcomes, such as new-onset diabetes and renal disease. Findings will be published in peer-reviewed medical journals on behalf of the collaboration.
- Published
- 2019
11. 2014 ESC guidelines on the diagnosis and treatment of aortic diseases
- Author
-
Erbel R, Aboyans, V, Boileau C, Bossone E, Di Bartolomeo R, Eggebrecht H, Evangelista A, Falk V, Frank H, Gaemperli O, Grabenwöger M, Haverich A, Iung B, Manolis AJ, Meijboom F, Nienaber CA, Roffi M, Rousseau H, Sechtem U, Sirnes PA, von Allmen RS, Vrints CJM, European Society of Cardiology (ESC), Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol Ç, Fagard R, Ferrari R, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S., Erbel, R, Aboyans, V, Boileau, C, Bossone, E, Di Bartolomeo, R, Eggebrecht, H, Evangelista, A, Falk, V, Frank, H, Gaemperli, O, Grabenwöger, M, Haverich, A, Iung, B, Manolis, Aj, Meijboom, F, Nienaber, Ca, Roffi, M, Rousseau, H, Sechtem, U, Sirnes, Pa, von Allmen, R, Vrints, Cjm, European Society of Cardiology, (ESC), Zamorano, Jl, Achenbach, S, Baumgartner, H, Bax, Jj, Bueno, H, Dean, V, Deaton, C, Erol, Ç, Fagard, R, Ferrari, R, Hasdai, D, Hoes, A, Kirchhof, P, Knuuti, J, Kolh, P, Lancellotti, P, Linhart, A, Nihoyannopoulos, P, Piepoli, Mf, Ponikowski, P, Tamargo, Jl, Tendera, M, Torbicki, A, Wijns, W, and Windecker, S.
- Published
- 2015
12. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy:the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)
- Author
-
Elliott P. M., Anastasakis A., Borger M. A., Borggrefe M., Cecchi F., Charron P., Hagege A. A., Lafont A., Limongelli G., Mahrholdt H., McKenna W. J., Mogensen J., Nihoyannopoulos P., Nistri S., Piepe P. G., Pieske B., Rapezzi C., Rutten F. H., Tillmanns C., Watkins H., O'Mahony C., Achenbach S., Baumgartner H., Bax J. J., Bueno H., Dean V., Deaton C., Erol C., Fagard R., Ferrari R., Hasdai D., Hoes A. W., Kirchhof P., Knuuti J., Kolh P., Lancellotti P., Linhart A., Piepoli M. F., Ponikowski P., Sirnes P. A., Tamargo J. L., Tendera M., Torbicki A., Wijns W., Windecker S., Alfonso F., Basso C., Cardim N. M., Gimeno J. R., Heymans S., Holm P. J., Keren A., Lionis C., Muneretto C., Priori S., Salvador M. J., Wolpert C., MUMC+: MA Med Staf Spec Cardiologie (9), Cardiologie, RS: CARIM - R2 - Cardiac function and failure, Elliott, P. M., Anastasakis, A., Borger, M. A., Borggrefe, M., Cecchi, F., Charron, P., Hagege, A. A., Lafont, A., Limongelli, G., Mahrholdt, H., Mckenna, W. J., Mogensen, J., Nihoyannopoulos, P., Nistri, S., Piepe, P. G., Pieske, B., Rapezzi, C., Rutten, F. H., Tillmanns, C., Watkins, H., O'Mahony, C., Achenbach, S., Baumgartner, H., Bax, J. J., Bueno, H., Dean, V., Deaton, C., Erol, C., Fagard, R., Ferrari, R., Hasdai, D., Hoes, A. W., Kirchhof, P., Knuuti, J., Kolh, P., Lancellotti, P., Linhart, A., Piepoli, M. F., Ponikowski, P., Sirnes, P. A., Tamargo, J. L., Tendera, M., Torbicki, A., Wijns, W., Windecker, S., Alfonso, F., Basso, C., Cardim, N. M., Gimeno, J. R., Heymans, S., Holm, P. J., Keren, A., Lionis, C., Muneretto, C., Priori, S., Salvador, M. J., and Wolpert, C.
- Subjects
Ablation Techniques ,Arrhythmia ,Athletes ,Cardiac imaging ,Diagnosis ,Genetics ,Guideline ,Heart failure ,Hypertension ,Implantable cardioverter defibrillators ,Left ventricular outflow tract obstruction ,Pregnancy ,Sudden cardiac death ,Symptoms ,Valve disease ,Cardiomyopathy ,Heart Valve Diseases ,Adult ,Angina Pectoris ,Arrhythmias ,Cardiac ,Cardiac Imaging Techniques ,Cardiac Pacing ,Artificial ,Hypertrophic ,Child ,Clinical Laboratory Techniques ,Death ,Sudden ,Delivery of Health Care ,Differential ,Electrocardiography ,Female ,Genetic Counseling ,Genetic Testing ,Heart Failure ,Humans ,Medical History Taking ,Pedigree ,Physical Examination ,Preconception Care ,Pregnancy Complications ,Cardiovascular ,Prenatal Care ,Risk Factors ,Sports Medicine ,Syncope ,Thoracic Surgical Procedures ,Ventricular Outflow Obstruction ,Cardiology and Cardiovascular Medicine ,Thoracic Surgical Procedure ,Clinical Laboratory Technique ,Implantable cardioverter defibrillator ,Ablation Technique ,Angina Pectori ,Hypertrophic cardiomyopathy ,Cardiac Pacing, Artificial ,Heart Valve Disease ,Cardiology ,Diagnosi ,Human ,Alcohol septal ablation ,medicine.medical_specialty ,Genetic counseling ,Symptom ,Pregnancy Complications, Cardiovascular ,610 Medicine & health ,NO ,Diagnosis, Differential ,Athlete ,Genetic ,Internal medicine ,medicine ,Guidline ,Intensive care medicine ,ta3126 ,Cardiac Imaging Technique ,business.industry ,Risk Factor ,Arrhythmias, Cardiac ,Cardiomyopathy, Hypertrophic ,medicine.disease ,Septal myectomy ,Death, Sudden, Cardiac ,business - Published
- 2014
13. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials
- Author
-
Agodoa, L, Anderson, C, Asselbergs, FW, Baigent, C, Black, H, Brenner, B, Brown, M, Bulpitt, C, Byington, R, Chalmers, J, Collins, R, Cutler, J, Dahlof, B, Davis, B, de Zeeuw, D, Dens, J, Estacio, R, Fagard, R, Fox, K, Fukui, T, Hansson, L, Holman, R, Hunsicker, L, Imai, Y, Ishii, M, Kanno, Y, Kostis, J, Kuramoto, K, Lewis, E, Lievre, M, Lindholm, LH, Liu, L, Lubsen, J, Lueders, S, MacMahon, S, Malacco, E, Mancia, G, Matsuzaki, M, Neal, B, Nissen, S, Ohkubo, T, Ogihara, T, Pepine, C, Pfeffer, M, Pitt, B, Poole-Wilson, P, Poulter, N, Rahman, M, Remme, W, Remuzzi, G, Rodgers, A, Ruggenenti, P, Saruta, T, Schrader, J, Schrier, R, Sever, P, Sleight, P, Staessen, J, Suzuki, H, Teo, K, van Gilst, WH, Viberti, G, Wang, J, Whelton, P, Wing, L, Yui, Y, Yusuf, S, Zanchetti, A, Barzi, F, Heritier, S, Li, N, Ninomiya, T, Perkovic, V, Turnbull, F, Woodward, M, Wilson, K, Kearney, ACP, Gallagher, M, Cass, A, Groningen Kidney Center (GKC), Cardiovascular Centre (CVC), Cardiology, Clinical Research Unit, Pathology, Graduate School, ACS - Heart failure & arrhythmias, and Amsterdam Reproduction & Development (AR&D)
- Subjects
medicine.medical_specialty ,Hemodynamics ,Renal function ,CONVERTING ENZYME-INHIBITOR ,PLACEBO-CONTROLLED TRIAL ,CALCIUM-ANTAGONIST ,DOUBLE-BLIND ,HYPERTENSIVE PATIENTS ,RISK-FACTOR ,Internal medicine ,medicine ,Myocardial infarction ,Intensive care medicine ,PUBLICATION BIAS ,biology ,business.industry ,Research ,Angiotensin-converting enzyme ,General Medicine ,medicine.disease ,RENAL OUTCOMES ,Blood pressure ,ATHEROSCLEROSIS ,Heart failure ,Cardiology ,Aortic pressure ,biology.protein ,CORONARY-ARTERY-DISEASE ,business ,Kidney disease - Abstract
Objective To define the cardiovascular effects of lowering blood pressure in people with chronic kidney disease.Design Collaborative prospective meta-analysis of randomised trials.Data sources and eligibility Participating randomised trials of drugs to lower blood pressure compared with placebo or each other or that compare different blood pressure targets, with at least 1000 patient years of follow-up per arm.Main outcome measures Major cardiovascular events (stroke, myocardial infarction, heart failure, or cardiovascular death) in composite and individually and all cause death.Participants 26 trials (152 290 participants), including 30 295 individuals with reduced estimated glomerular filtration rate (eGFR), which was defined as eGFRData extraction Individual participant data were available for 23 trials, with summary data from another three. Meta-analysis according to baseline kidney function was performed. Pooled hazard ratios per 5 mm Hg lower blood pressure were estimated with a random effects model.Results Compared with placebo, blood pressure lowering regimens reduced the risk of major cardiovascular events by about a sixth per 5 mm Hg reduction in systolic blood pressure in individuals with (hazard ratio 0.83, 95% confidence interval 0.76 to 0.90) and without reduced eGFR (0.83, 0.79 to 0.88), with no evidence for any difference in effect (P=1.00 for homogeneity). The results were similar irrespective of whether blood pressure was reduced by regimens based on angiotensin converting enzyme inhibitors, calcium antagonists, or diuretics/beta blockers. There was no evidence that the effects of different drug classes on major cardiovascular events varied between patients with different eGFR (all P>0.60 for homogeneity).Conclusions Blood pressure lowering is an effective strategy for preventing cardiovascular events among people with moderately reduced eGFR. There is little evidence from these overviews to support the preferential choice of particular drug classes for the prevention of cardiovascular events in chronic kidney disease.
- Published
- 2016
14. Erratum: 'European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)' the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)
- Author
-
Perk, J, De Backer, G, Gohlke, H, Graham, I, Reiner, Z, Verschuren, WMM, Albus, C, Benlian, P, Boysen, G, Cifkova, R, Deaton, C, Ebrahim, S, Fisher, M, Germano, G, Hobbs, R, Hoes, A, Karadeniz, S, Mezzani, A, Prescott, E, Ryden, L, Scherer, M, Syvänne, M, Scholte Op Reimer, WJ, Vrints, C, Wood, D, Zamorano, JL, Zannad, F, Cooney, MT, Bax, J, Baumgartner, H, Ceconi, C, Dean, V, Fagard, R, Funck-Brentano, C, Hasdai, D, Kirchhof, P, Knuuti, J, Kolh, P, McDonagh, T, Moulin, C, Popescu, BA, Reiner, Ž, Sechtem, U, Sirnes, PA, Tendera, M, Torbicki, A, Vahanian, A, Windecker, S, Aboyans, V, Ezquerra, EA, Baigent, C, Brotons, C, Burell, G, Ceriello, A, De Sutter, J, Deckers, J, Del Prato, S, Diener, HC, Fitzsimons, D, Fras, Z, Hambrecht, R, Jankowski, P, Keil, U, Kirby, M, Larsen, ML, Mancia, G, Manolis, AJ, McMurray, J, Pajak, A, Parkhomenko, A, Rallidis, L, Rigo, F, Rocha, E, Ruilope, LM, Van Der Velde, E, Vanuzzo, D, Viigimaa, M, Volpe, M, Wiklund, O, and Wolpert, C
- Subjects
Clinical Practice ,medicine.medical_specialty ,Rehabilitation ,Cardiovascular prevention ,Task force ,business.industry ,medicine.medical_treatment ,Alternative medicine ,medicine ,Physical therapy ,Disease prevention ,Cardiology and Cardiovascular Medicine ,business - Published
- 2016
15. Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration
- Author
-
Black, H, Boissel, J, Brenner, B, Brown, M, Bulpitt, C, Chalmers, J, Collins, R, Cutler, J, Dahlof, B, Davis, B, Fagard, R, Fletcher, A, Furberg, C, Hansson, L, Kuramoto, K, Lewis, E, MacMahon, S, Mancia, G, Pitt, B, Poulter, N, Remuzzi, G, Sleight, P, Turner, R, Sever, P, and Whelton, P
- Abstract
OBJECTIVE: To conduct prospectively planned overviews (meta-analyses) of the ongoing randomized trials of blood-pressure-lowering drugs. These overviews should provide reliable data about the effects of newer classes of blood-pressure-lowering drugs (such as angiotensin converting enzyme inhibitors and calcium antagonists) on major causes of cardiovascular mortality and morbidity for a variety of patient groups. METHODS: A registry of major ongoing or planned randomized trials (with more than 1000 patient-years of follow-up for each randomized group) of blood-pressure-lowering agents has been established. The principal investigators of each of these studies have been invited to collaborate in the project and to provide, upon completion of the study, a limited data set for inclusion in the overview analyses. The principal comparisons will be of newer versus older classes of blood-pressure-lowering drugs in treating patients with hypertension and of newer blood-pressure-lowering treatments versus untreated or less treated control conditions for a variety of other groups of patients with a high risk of cardiovascular events. Separate analyses will be conducted for the main drug classes and for major subgroups of patients defined by characteristics such as age, gender, blood pressure, diabetes, and history of renal disease, coronary heart disease or cerebrovascular disease. The principal study outcomes are stroke, major coronary heart disease events, heart failure, total cardiovascular deaths, total cardiovascular events and total mortality. RESULTS: In total 36 trials of blood-pressure-lowering treatments potentially eligible for inclusion in this project have been identified and agreement to collaborate has been confirmed by the investigators in 30 trials, with collaboration pending for six recently identified studies. The first round of analyses will be conducted in 1999 and will be based on total cardiovascular events observed among a total of about 64,000 patients, involving about 240,000 patient-years of follow-up. The second round of analyses will be conducted in 2003 on data from at least 195,000 patients and 899,000 patient-years of follow-up. By that time it is estimated that a total of about 8000 strokes, 12,000 coronary heart disease events and 23,000 cardiovascular events in total will have occurred. This should provide good statistical power to detect even modest cause-specific differences in the incidence of the main study outcomes. CONCLUSIONS: The combination of trial results in prospectively planned, systematic overviews both reduces random errors and avoids biases. As a consequence, this project should provide more reliable information about the effects of newer blood-pressure-lowering drugs than would any one study alone. The use of data from individual patients in these overviews will facilitate investigation of the separate effects of various drug regimens in treating members of major patient subgroups.
- Published
- 2016
16. Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index : A meta-analysis of randomised trials
- Author
-
Agodoa, L., Estacio, R., Schrier, R., Lubsen, J., Chalmers, J., Cutler, J., Davis, B., Wing, L., Poulter, N. R., Sever, P., Remuzzi, G., Ruggenenti, P., Nissen, S., Lindholm, L. H., Fukui, T., Ogihara, T., Saruta, T., Black, H., Sleight, P., Lievre, M., Suzuki, H., Fox, K., Lisheng, L., Ohkubo, T., Imai, Y., Yusuf, S., Bulpitt, C. J., Lewis, E., Brown, M., Palmer, C., Wang, J., Pepine, C., Ishii, M., Yui, Y., Kuramoto, K., Pfeff Er, M., Asselbergs, F. W., Van Gilst, W. H., Byington, B., Pitt, B., Brenner, B., Remme, W. J., De Zeeuw, D., Rahman, M., Viberti, G., Teo, K., Zanchetti, A., Malacco, E., Mancia, G., Staessen, J., Fagard, R., Holman, R., Hansson, L., Kostis, J., Kanno, Y., Lueders, S., Matsuzaki, M., Poole-Wilson, P., Schrader, J., Rahimi, K., Anderson, C., Chapman, N., Collins, R., MacMahon, S., Neal, B., Rodgers, A., Whelton, P., Woodward, M., Cardiovascular Centre (CVC), Groningen Kidney Center (GKC), Epidemiology and Data Science, Graduate School, APH - Methodology, and APH - Personalized Medicine
- Subjects
medicine.medical_specialty ,DISEASE ,Body Mass Index ,EVENTS ,Internal medicine ,medicine ,Humans ,Obesity ,Stroke ,Antihypertensive Agents ,METABOLIC SYNDROME ,Randomized Controlled Trials as Topic ,Medicine(all) ,business.industry ,MORTALITY ,Hazard ratio ,General Medicine ,medicine.disease ,PREVENTION ,EUROPEAN-SOCIETY ,PROSPECTIVELY-DESIGNED OVERVIEWS ,REDUCTION ,Blood pressure ,Cardiovascular Diseases ,Heart failure ,Meta-analysis ,Hypertension ,Physical therapy ,Metabolic syndrome ,business ,Body mass index ,Risk Reduction Behavior - Abstract
Summary Background The cardiovascular benefits of blood pressure lowering in obese people compared with people of normal weight might depend on choice of drug. We compared the effects of blood pressure-lowering regimens on cardiovascular risk in groups of patients categorised by baseline body-mass index (BMI). Methods We used individual patient data from trials included in the Blood Pressure Lowering Treatment Trialists' Collaboration to compare the effects of different classes of blood pressure-lowering regimens for the primary outcome of total major cardiovascular events (stroke, coronary heart disease, heart failure, and cardiovascular death). We used meta-analyses and meta-regressions to assess interactions between treatment and BMI when fitted as either a categorical variable (0·20). When analysed as a continuous variable, angiotensin-converting-enzyme inhibitors gave slightly greater protection for each 5 kg/m2 higher BMI than did calcium antagonists (hazard ratio 0·93, 95% CI 0·89-0·98; p=0·004) or diuretics (0·93, 0·89-0·98; p=0·002). The meta-regressions showed no relation between BMI category and the risk reduction for a given fall in systolic blood pressure. By contrast with a previous report, we noted no relation between BMI and the efficacy of calcium antagonists compared with diuretics. Interpretation We found little evidence that selection of a particular class of blood pressure-lowering drug will lead to substantially different outcomes for individuals who are obese compared with those who are lean. Funding None.
- Published
- 2015
17. Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: A meta-analysis of randomised trials
- Author
-
Cardiologie, Circulatory Health, Agodoa, L., Estacio, R., Schrier, R., Lubsen, J., Chalmers, J., Cutler, J., Davis, B., Wing, L., Poulter, N. R., Sever, P., Remuzzi, G., Ruggenenti, P., Nissen, S., Lindholm, L. H., Fukui, T., Ogihara, T., Saruta, T., Black, H., Sleight, P., Lievre, M., Suzuki, H., Fox, K., Lisheng, L., Ohkubo, T., Imai, Y., Yusuf, S., Bulpitt, C. J., Lewis, E., Brown, M., Palmer, C., Wang, J., Pepine, C., Ishii, M., Yui, Y., Kuramoto, K., Pfeff Er, M., Asselbergs, F. W., Van Gilst, W. H., Byington, B., Pitt, B., Brenner, B., Remme, W. J., De Zeeuw, D., Rahman, M., Viberti, G., Teo, K., Zanchetti, A., Malacco, E., Mancia, G., Staessen, J., Fagard, R., Holman, R., Hansson, L., Kostis, J., Kanno, Y., Lueders, S., Matsuzaki, M., Poole-Wilson, P., Schrader, J., Rahimi, K., Anderson, C., Chapman, N., Collins, R., MacMahon, S., Neal, B., Rodgers, A., Whelton, P., Woodward, M., Cardiologie, Circulatory Health, Agodoa, L., Estacio, R., Schrier, R., Lubsen, J., Chalmers, J., Cutler, J., Davis, B., Wing, L., Poulter, N. R., Sever, P., Remuzzi, G., Ruggenenti, P., Nissen, S., Lindholm, L. H., Fukui, T., Ogihara, T., Saruta, T., Black, H., Sleight, P., Lievre, M., Suzuki, H., Fox, K., Lisheng, L., Ohkubo, T., Imai, Y., Yusuf, S., Bulpitt, C. J., Lewis, E., Brown, M., Palmer, C., Wang, J., Pepine, C., Ishii, M., Yui, Y., Kuramoto, K., Pfeff Er, M., Asselbergs, F. W., Van Gilst, W. H., Byington, B., Pitt, B., Brenner, B., Remme, W. J., De Zeeuw, D., Rahman, M., Viberti, G., Teo, K., Zanchetti, A., Malacco, E., Mancia, G., Staessen, J., Fagard, R., Holman, R., Hansson, L., Kostis, J., Kanno, Y., Lueders, S., Matsuzaki, M., Poole-Wilson, P., Schrader, J., Rahimi, K., Anderson, C., Chapman, N., Collins, R., MacMahon, S., Neal, B., Rodgers, A., Whelton, P., and Woodward, M.
- Published
- 2015
18. Systolic blood pressure variation and mean heart rate is associated with cognitive dysfunction in patients with high cardiovascular risk
- Author
-
Böhm, M, Schumacher, H, Leong, D, Mancia, G, Unger, T, Schmieder, R, Custodis, F, Diener, H, Laufs, U, Lonn, E, Sliwa, K, Teo, K, Fagard, R, Redon, J, Sleight, P, Anderson, C, O'Donnell, M, Yusuf, S, Böhm, Michael, Schumacher, Helmut, Leong, Darryl, Mancia, Giuseppe, Unger, Thomas, Schmieder, Roland, Custodis, Florian, Diener, Hans-Christoph, Laufs, Ulrich, Lonn, Eva, Sliwa, Karen, Teo, Koon, Fagard, Robert, Redon, Josep, Sleight, Peter, Anderson, Craig, O'Donnell, Martin, Yusuf, Salim, Böhm, M, Schumacher, H, Leong, D, Mancia, G, Unger, T, Schmieder, R, Custodis, F, Diener, H, Laufs, U, Lonn, E, Sliwa, K, Teo, K, Fagard, R, Redon, J, Sleight, P, Anderson, C, O'Donnell, M, Yusuf, S, Böhm, Michael, Schumacher, Helmut, Leong, Darryl, Mancia, Giuseppe, Unger, Thomas, Schmieder, Roland, Custodis, Florian, Diener, Hans-Christoph, Laufs, Ulrich, Lonn, Eva, Sliwa, Karen, Teo, Koon, Fagard, Robert, Redon, Josep, Sleight, Peter, Anderson, Craig, O'Donnell, Martin, and Yusuf, Salim
- Abstract
Supplemental Digital Content is available in the text. Abstract - Elevated systolic blood pressure (SBP) correlates to cognitive decline and incident dementia. The effects of heart rate (HR), visit to visit HR variation, and visit to visit SBP variation are less well established. Patients without preexisting cognitive dysfunction (N=24 593) were evaluated according to mean SBP, SBP visit to visit variation (coefficient of variation [standard deviation/mean×100%], CV), mean HR, and visit to visit HR variation (HR-CV) in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease. Cognitive function was assessed with mini mental state examination. Cognitive dysfunction (fall in mini mental state examination ≤24 points), important cognitive decline (drop of ≥5 points), and cognitive deterioration (drop of >1 point per year or decline to <24 points) were assessed. SBP and HR were measured over 10.7±2.2 (mean±SD) visits. Mean SBP, mean HR, and SBP-CV were associated with cognitive decline, dysfunction, and deterioration (all P<0.01, unadjusted). After adjustment, only SBP-CV (P=0.0030) and mean HR (P=0.0008) remained predictors for cognitive dysfunction (odds ratios [95% confidence intervals], 1.32 [1.10-1.58] for 5th versus 1st quintile of SBP-CV and 1.40 [1.18-1.66] for 5th versus 1st quintile of mean HR). Similar effects were observed for cognitive decline and deterioration. SBP-CV and mean HR showed additive effects. In conclusion, SBP-CV and mean HR are independent predictors of cognitive decline and cognitive dysfunction in patients at high CV risk. Clinical Trial Registration - URL: http://www.clinicaltrials.gov. Unique identifier: NCT 00153101.
- Published
- 2015
19. Systolic Blood Pressure Variation and Mean Heart Rate Is Associated With Cognitive Dysfunction in Patients With High Cardiovascular Risk
- Author
-
Ulrich Laufs, Hans-Christoph Diener, Craig S. Anderson, Florian Custodis, Robert Fagard, Eva Lonn, Peter Sleight, Roland E. Schmieder, Salim Yusuf, Helmut Schumacher, Thomas Unger, Karen Sliwa, Martin O'Donnell, Giuseppe Mancia, Koon K. Teo, Josep Redon, Michael Böhm, Darryl P. Leong, Böhm, M, Schumacher, H, Leong, D, Mancia, G, Unger, T, Schmieder, R, Custodis, F, Diener, H, Laufs, U, Lonn, E, Sliwa, K, Teo, K, Fagard, R, Redon, J, Sleight, P, Anderson, C, O'Donnell, M, Yusuf, S, Bedrijfsbureau CD, and RS: CARIM - R3 - Vascular biology
- Subjects
Male ,Predictive Value of Test ,Angiotensin-Converting Enzyme Inhibitors ,Blood Pressure ,Benzimidazole ,Benzoates ,Ramipril ,Retrospective Studie ,Heart Rate ,Risk Factors ,Cardiovascular Disease ,Telmisartan ,Cognitive decline ,Multivariate Analysi ,Randomized Controlled Trials as Topic ,Aged, 80 and over ,medicine.diagnostic_test ,Incidence ,Middle Aged ,stroke ,Antihypertensive Agent ,myocardial infarction ,Cardiovascular Diseases ,Hypertension ,Cardiology ,Drug Therapy, Combination ,Female ,Human ,medicine.drug ,medicine.medical_specialty ,Benzoate ,Follow-Up Studie ,Cognition Disorder ,Predictive Value of Tests ,Internal medicine ,Heart rate ,Internal Medicine ,medicine ,Humans ,Dementia ,Antihypertensive Agents ,Aged ,Retrospective Studies ,Mini–Mental State Examination ,business.industry ,Risk Factor ,Angiotensin-Converting Enzyme Inhibitor ,Odds ratio ,medicine.disease ,Confidence interval ,Blood pressure ,Multivariate Analysis ,Physical therapy ,Benzimidazoles ,Cognition Disorders ,business ,Follow-Up Studies - Abstract
Abstract— Elevated systolic blood pressure (SBP) correlates to cognitive decline and incident dementia. The effects of heart rate (HR), visit to visit HR variation, and visit to visit SBP variation are less well established. Patients without preexisting cognitive dysfunction (N=24 593) were evaluated according to mean SBP, SBP visit to visit variation (coefficient of variation [standard deviation/mean×100%], CV), mean HR, and visit to visit HR variation (HR-CV) in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease. Cognitive function was assessed with mini mental state examination. Cognitive dysfunction (fall in mini mental state examination ≤24 points), important cognitive decline (drop of ≥5 points), and cognitive deterioration (drop of >1 point per year or decline to < 24 points) were assessed. SBP and HR were measured over 10.7±2.2 (mean±SD) visits. Mean SBP, mean HR, and SBP-CV were associated with cognitive decline, dysfunction, and deterioration (all P P =0.0030) and mean HR ( P =0.0008) remained predictors for cognitive dysfunction (odds ratios [95% confidence intervals], 1.32 [1.10–1.58] for 5th versus 1st quintile of SBP-CV and 1.40 [1.18–1.66] for 5th versus 1st quintile of mean HR). Similar effects were observed for cognitive decline and deterioration. SBP-CV and mean HR showed additive effects. In conclusion, SBP-CV and mean HR are independent predictors of cognitive decline and cognitive dysfunction in patients at high CV risk. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT 00153101.
- Published
- 2015
20. Exercise Prescription in Patients with Different Combinations of Cardiovascular Disease Risk Factors: A Consensus Statement from the EXPERT Working Group.
- Author
-
Hansen D, Niebauer J, Cornelissen V, Barna O, Neunhäuserer D, Stettler C, Tonoli C, Greco E, Fagard R, Coninx K, Vanhees L, Piepoli MF, Pedretti R, Ruiz GR, Corrà U, Schmid JP, Davos CH, Edelmann F, Abreu A, Rauch B, Ambrosetti M, Braga SS, Beckers P, Bussotti M, Faggiano P, Garcia-Porrero E, Kouidi E, Lamotte M, Reibis R, Spruit MA, Takken T, Vigorito C, Völler H, Doherty P, and Dendale P
- Subjects
- Cardiovascular Diseases diagnosis, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Female, Hand Strength, Humans, Male, Risk Factors, Treatment Outcome, Cardiac Rehabilitation standards, Cardiovascular Diseases prevention & control, Consensus, Exercise physiology, Exercise Therapy standards, Preventive Health Services standards
- Abstract
Whereas exercise training is key in the management of patients with cardiovascular disease (CVD) risk (obesity, diabetes, dyslipidaemia, hypertension), clinicians experience difficulties in how to optimally prescribe exercise in patients with different CVD risk factors. Therefore, a consensus statement for state-of-the-art exercise prescription in patients with combinations of CVD risk factors as integrated into a digital training and decision support system (the EXercise Prescription in Everyday practice & Rehabilitative Training (EXPERT) tool) needed to be established. EXPERT working group members systematically reviewed the literature for meta-analyses, systematic reviews and/or clinical studies addressing exercise prescriptions in specific CVD risk factors and formulated exercise recommendations (exercise training intensity, frequency, volume and type, session and programme duration) and exercise safety precautions, for obesity, arterial hypertension, type 1 and 2 diabetes, and dyslipidaemia. The impact of physical fitness, CVD risk altering medications and adverse events during exercise testing was further taken into account to fine-tune this exercise prescription. An algorithm, supported by the interactive EXPERT tool, was developed by Hasselt University based on these data. Specific exercise recommendations were formulated with the aim to decrease adipose tissue mass, improve glycaemic control and blood lipid profile, and lower blood pressure. The impact of medications to improve CVD risk, adverse events during exercise testing and physical fitness was also taken into account. Simulations were made of how the EXPERT tool provides exercise prescriptions according to the variables provided. In this paper, state-of-the-art exercise prescription to patients with combinations of CVD risk factors is formulated, and it is shown how the EXPERT tool may assist clinicians. This contributes to an appropriately tailored exercise regimen for every CVD risk patient.
- Published
- 2018
- Full Text
- View/download PDF
21. The European Association of Preventive Cardiology Exercise Prescription in Everyday Practice and Rehabilitative Training (EXPERT) tool: A digital training and decision support system for optimized exercise prescription in cardiovascular disease. Concept, definitions and construction methodology.
- Author
-
Hansen D, Dendale P, Coninx K, Vanhees L, Piepoli MF, Niebauer J, Cornelissen V, Pedretti R, Geurts E, Ruiz GR, Corrà U, Schmid JP, Greco E, Davos CH, Edelmann F, Abreu A, Rauch B, Ambrosetti M, Braga SS, Barna O, Beckers P, Bussotti M, Fagard R, Faggiano P, Garcia-Porrero E, Kouidi E, Lamotte M, Neunhäuserer D, Reibis R, Spruit MA, Stettler C, Takken T, Tonoli C, Vigorito C, Völler H, and Doherty P
- Subjects
- Cardiac Rehabilitation adverse effects, Cardiovascular Diseases diagnosis, Cardiovascular Diseases epidemiology, Cardiovascular Diseases physiopathology, Exercise Therapy adverse effects, Exercise Tolerance, Humans, Predictive Value of Tests, Risk Assessment, Risk Factors, Treatment Outcome, Cardiac Rehabilitation standards, Cardiovascular Diseases prevention & control, Decision Support Techniques, Exercise Therapy standards, Preventive Health Services standards
- Abstract
Background Exercise rehabilitation is highly recommended by current guidelines on prevention of cardiovascular disease, but its implementation is still poor. Many clinicians experience difficulties in prescribing exercise in the presence of different concomitant cardiovascular diseases and risk factors within the same patient. It was aimed to develop a digital training and decision support system for exercise prescription in cardiovascular disease patients in clinical practice: the European Association of Preventive Cardiology Exercise Prescription in Everyday Practice and Rehabilitative Training (EXPERT) tool. Methods EXPERT working group members were requested to define (a) diagnostic criteria for specific cardiovascular diseases, cardiovascular disease risk factors, and other chronic non-cardiovascular conditions, (b) primary goals of exercise intervention, (c) disease-specific prescription of exercise training (intensity, frequency, volume, type, session and programme duration), and (d) exercise training safety advices. The impact of exercise tolerance, common cardiovascular medications and adverse events during exercise testing were further taken into account for optimized exercise prescription. Results Exercise training recommendations and safety advices were formulated for 10 cardiovascular diseases, five cardiovascular disease risk factors (type 1 and 2 diabetes, obesity, hypertension, hypercholesterolaemia), and three common chronic non-cardiovascular conditions (lung and renal failure and sarcopaenia), but also accounted for baseline exercise tolerance, common cardiovascular medications and occurrence of adverse events during exercise testing. An algorithm, supported by an interactive tool, was constructed based on these data. This training and decision support system automatically provides an exercise prescription according to the variables provided. Conclusion This digital training and decision support system may contribute in overcoming barriers in exercise implementation in common cardiovascular diseases.
- Published
- 2017
- Full Text
- View/download PDF
22. The effects of missed doses of amlodipine and losartan on blood pressure in older hypertensive patients.
- Author
-
de Leeuw PW, Fagard R, and Kroon AA
- Subjects
- Aged, Aged, 80 and over, Double-Blind Method, Female, Humans, Male, Treatment Outcome, Amlodipine administration & dosage, Antihypertensive Agents administration & dosage, Blood Pressure drug effects, Hypertension drug therapy, Losartan administration & dosage
- Abstract
This randomized, double-blind, parallel-group, multicenter study compared the efficacy of amlodipine and losartan in an older hypertensive population, focusing on therapeutic coverage in the case of missed doses. Following a 4-week, single-blind, placebo washout period, 211 patients were randomly assigned to receive either 5 mg of amlodipine once daily or 50 mg of losartan once daily. Doses were doubled after 6 weeks of treatment if the diastolic blood pressure exceeded 90 mm Hg. After the 12-week treatment period, patients received the placebo for 2 days (drug holiday) to simulate two missed doses of antihypertensive medication. Twenty-four-hour ambulatory blood pressure monitoring was conducted at the end of the placebo washout period (baseline), upon completion of the 12-week treatment period (steady state), and after the 2-day drug holiday. Amlodipine was more effective than losartan in reducing patients' 24-h ambulatory blood pressure at the steady-state sampling time. The increases in 24-h blood pressure during the drug holiday averaged 6±2/2±1 mm Hg (P<0.0001) in the amlodipine group and 3±2/2±1 mm Hg (P<0.0001) in the losartan group. The rise in systolic pressure was greater in patients on amlodipine than in those on losartan (P<0.0001). For diastolic pressure, the changes did not differ. Owing to the lower pressure during treatment, patients in the amlodipine group remained at a significantly lower blood pressure level after the 2-day drug holiday. Amlodipine was more effective than losartan in lowering blood pressure and in maintaining blood pressure control after two missed doses, and the difference was most significant for systolic blood pressure.
- Published
- 2017
- Full Text
- View/download PDF
23. Cellular response to alkylating agent MNNG is impaired in STAT1-deficients cells.
- Author
-
Ah-Koon L, Lesage D, Lemadre E, Souissi I, Fagard R, Varin-Blank N, Fabre EE, and Schischmanoff O
- Subjects
- Cell Cycle drug effects, Cell Death drug effects, Cell Line, Tumor, Cell Survival drug effects, Checkpoint Kinase 2 metabolism, Cytoprotection drug effects, DNA metabolism, DNA Breaks, Double-Stranded drug effects, Histones metabolism, Humans, Imatinib Mesylate pharmacology, Protein Isoforms metabolism, Proto-Oncogene Proteins c-abl metabolism, STAT1 Transcription Factor metabolism, Tumor Suppressor Protein p53 metabolism, Alkylating Agents pharmacology, Methylnitronitrosoguanidine pharmacology, STAT1 Transcription Factor deficiency
- Abstract
The SN 1 alkylating agents activate the mismatch repair system leading to delayed G2 /M cell cycle arrest and DNA repair with subsequent survival or cell death. STAT1, an anti-proliferative and pro-apoptotic transcription factor is known to potentiate p53 and to affect DNA-damage cellular response. We studied whether STAT1 may modulate cell fate following activation of the mismatch repair system upon exposure to the alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine (MNNG). Using STAT1-proficient or -deficient cell lines, we found that STAT1 is required for: (i) reduction in the extent of DNA lesions, (ii) rapid phosphorylation of T68-CHK2 and of S15-p53, (iii) progression through the G2 /M checkpoint and (iv) long-term survival following treatment with MNNG. Presence of STAT1 is critical for the formation of a p53-DNA complex comprising: STAT1, c-Abl and MLH1 following exposure to MNNG. Importantly, presence of STAT1 allows recruitment of c-Abl to p53-DNA complex and links c-Abl tyrosine kinase activity to MNNG-toxicity. Thus, our data highlight the important modulatory role of STAT1 in the signalling pathway activated by the mismatch repair system. This ability of STAT1 to favour resistance to MNNG indicates the targeting of STAT1 pathway as a therapeutic option for enhancing the efficacy of SN1 alkylating agent-based chemotherapy., (© 2016 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.)
- Published
- 2016
- Full Text
- View/download PDF
24. Specific genetic influences on nighttime blood pressure.
- Author
-
Xu X, Su S, Treiber FA, Vlietinck R, Fagard R, Derom C, Gielen M, Loos RJ, Snieder H, and Wang X
- Subjects
- Adolescent, Adult, Blood Pressure Monitoring, Ambulatory, Female, Genotype, Heredity, Humans, Male, Phenotype, Prospective Studies, Time Factors, Young Adult, Blood Pressure genetics, Circadian Rhythm genetics, Twins genetics
- Abstract
Objectives: Nighttime blood pressure (BP) has been shown to be superior to daytime BP in predicting hypertension related target organ damage and cardiac mortality. In our Georgia Cardiovascular Twin Study, we showed that apart from the genes that also influence daytime BP, specific genetic determinants explained 44% and 67% of the nighttime systolic BP (SBP) and diastolic BP (DBP) heritabilities, respectively. Here, we determined whether these results could be confirmed in a much larger twin cohort of young adults with 24-hour ambulatory BP measurements., Methods: Ambulatory BP was available in 703 white twins (308 pairs and 87 singletons, aged 18-34 years, 50% males) from the Prenatal Programming Twin Study. A bivariate quantitative genetic twin model was used to analyze daytime and nighttime BP. We conducted a meta-analysis to compare and integrate results from the 2 twin cohorts., Results: Model fitting showed no sex differences for any of the measures. Heritabilities were 0.60 and 0.51 for SBP and 0.54 and 0.46 for DBP at daytime and nighttime. The specific heritability due to novel genetic effects emerging during the nighttime was 0.21 for SBP and 0.26 for DBP, which comprised 41% and 57% of the total nighttime heritability for SBP and DBP, respectively. Meta-analysis confirmed absence of cohort differences with very similar combined results., Conclusions: In addition to genes that influence both daytime and nighttime BP, a large part of the heritability is explained by genes that specifically influence BP at night., (© American Journal of Hypertension, Ltd 2014. All rights reserved. For Permissions, please email: journals.permissions@oup.com.)
- Published
- 2015
- Full Text
- View/download PDF
25. Systolic blood pressure variation and mean heart rate is associated with cognitive dysfunction in patients with high cardiovascular risk.
- Author
-
Böhm M, Schumacher H, Leong D, Mancia G, Unger T, Schmieder R, Custodis F, Diener HC, Laufs U, Lonn E, Sliwa K, Teo K, Fagard R, Redon J, Sleight P, Anderson C, O'Donnell M, and Yusuf S
- Subjects
- Aged, Aged, 80 and over, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Antihypertensive Agents therapeutic use, Benzimidazoles therapeutic use, Benzoates therapeutic use, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Hypertension drug therapy, Incidence, Male, Middle Aged, Multivariate Analysis, Predictive Value of Tests, Ramipril therapeutic use, Randomized Controlled Trials as Topic, Retrospective Studies, Risk Factors, Telmisartan, Blood Pressure physiology, Cardiovascular Diseases epidemiology, Cognition Disorders epidemiology, Heart Rate physiology, Hypertension complications, Hypertension physiopathology
- Abstract
Unlabelled: Elevated systolic blood pressure (SBP) correlates to cognitive decline and incident dementia. The effects of heart rate (HR), visit to visit HR variation, and visit to visit SBP variation are less well established. Patients without preexisting cognitive dysfunction (N=24 593) were evaluated according to mean SBP, SBP visit to visit variation (coefficient of variation [standard deviation/mean×100%], CV), mean HR, and visit to visit HR variation (HR-CV) in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease. Cognitive function was assessed with mini mental state examination. Cognitive dysfunction (fall in mini mental state examination ≤24 points), important cognitive decline (drop of ≥5 points), and cognitive deterioration (drop of >1 point per year or decline to <24 points) were assessed. SBP and HR were measured over 10.7±2.2 (mean±SD) visits. Mean SBP, mean HR, and SBP-CV were associated with cognitive decline, dysfunction, and deterioration (all P<0.01, unadjusted). After adjustment, only SBP-CV (P=0.0030) and mean HR (P=0.0008) remained predictors for cognitive dysfunction (odds ratios [95% confidence intervals], 1.32 [1.10-1.58] for 5th versus 1st quintile of SBP-CV and 1.40 [1.18-1.66] for 5th versus 1st quintile of mean HR). Similar effects were observed for cognitive decline and deterioration. SBP-CV and mean HR showed additive effects. In conclusion, SBP-CV and mean HR are independent predictors of cognitive decline and cognitive dysfunction in patients at high CV risk., Clinical Trial Registration Url: http://www.clinicaltrials.gov. Unique identifier: NCT 00153101., (© 2015 American Heart Association, Inc.)
- Published
- 2015
- Full Text
- View/download PDF
26. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
- Author
-
Kolh P, Windecker S, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol Ç, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Sousa Uva M, Achenbach S, Pepper J, Anyanwu A, Badimon L, Bauersachs J, Baumbach A, Beygui F, Bonaros N, De Carlo M, Deaton C, Dobrev D, Dunning J, Eeckhout E, Gielen S, Hasdai D, Kirchhof P, Luckraz H, Mahrholdt H, Montalescot G, Paparella D, Rastan AJ, Sanmartin M, Sergeant P, Silber S, Tamargo J, ten Berg J, Thiele H, van Geuns RJ, Wagner HO, Wassmann S, Wendler O, and Zamorano JL
- Subjects
- Europe, Female, Humans, Male, Thoracic Surgery organization & administration, Thoracic Surgery standards, Myocardial Revascularization methods, Myocardial Revascularization standards
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.